PYXS (Pyxis Oncology) Moat Score: 2/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PYXS Pyxis Oncology Inc PYXS
27 GF Score
Price $3.32
! 4 Warning Signs
View Full Analysis

What is Pyxis Oncology Moat Score?

Pyxis Oncology PYXS +4.25% 27 Moat Score is 2 as of Aug. 13, 2026. GuruFocus rates PYXS with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,388 Biotechnology companies, Pyxis Oncology ranks better than 58.43% on this metric.

Pyxis Oncology has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Pyxis Oncology has No Moat: Pyxis Oncology Inc lacks a discernible moat due to its early-stage development and absence of market leadership or significant intellectual property. The company faces high competition and regulatory hurdles in the biotech industry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pyxis Oncology might have No Moat - Very weak/transient advantages.

Pyxis Oncology  (NAS:PYXS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pyxis Oncology Moat Score Related Terms

PYXS vs ORMP, CAMP, ALEC: Moat Score Comparison

For the Biotechnology subindustry, Pyxis Oncology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pyxis Oncology Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Moat Score distribution charts can be found below:

* The bar in red indicates where Pyxis Oncology's Moat Score falls into.


PYXS
27GF Score
Pyxis Oncology Inc PYXS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Pyxis Oncology (PYXS) has a Moat Score of 2 as of Aug. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pyxis Oncology ranks #577 out of 1388 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Pyxis Oncology's Moat Score too high?
Pyxis Oncology's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Pyxis Oncology's value of 2 is 0% at this industry median. Based on the distribution chart, Pyxis Oncology ranks #577 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pyxis Oncology has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Moat Score compare to ORMP and CAMP?
According to the Biotechnology industry distribution chart, Pyxis Oncology ranks #577 out of 1388 companies for Moat Score. This puts Pyxis Oncology in the upper half of its industry. The industry median Moat Score is 2.00. Pyxis Oncology's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pyxis Oncology's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pyxis Oncology's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Pyxis Oncology's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Moat Score is 2 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pyxis Oncology Business Description

Address 321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
27GF Score

Get the complete analysis for PYXS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price